FDA Policy/General

Latest FDA Warning Letters

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

Diamond Wipes International Chino, CA (3/7): FDA inspected the firm 5/2017 and cited significant GMP violations for finished pharmaceuticals. For example, the company failed to establish written procedures for production and process controls designed to assure that the drug products manufactured have the identity, strength, quality, and purity they purport. Additionally, the firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm600638.htm

Labocont Industrial Santo Domingo, Dominican Republic (3/9): FDA inspected the firm June 2017 and cited significant GMP violations for finished pharmaceuticals. For example, the firm failed to perform operations within specifically defined areas and to have separate or defined areas necessary to prevent contamination or mix-ups. In addition, the firm failed to ensure that laboratory records included complete data derived from all tests necessary to assure compliance with established specifications and standards.
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm601181.htm

Malladi Drugs & Pharmaceuticals Chennai, India (3/9): FDA inspected the form in September 2017 and cited significant GMP deviations for active pharmaceutical ingredients. For example, the firm failed to use appropriate precautions to minimize the risk of API contamination where open equipment is used. In addition, it failed to have equipment of the appropriate design and suitability for its intended use.
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm600931.htm

Vilex in Tennessee McMinnville, TN (1/9): FDA inspected the firm 8/2017 and cited GMP deficiencies with its medical devices. For example, the firm failed to establish design history files. In addition, the firm failed to adequately establish procedures for design validation.
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm600759.htm

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome